Pozen plans trial of PN 200 for arthritis

By Lisa Kerner

Erie, Pa., April 20 - Pozen, Inc. completed a Special Protocol Assessment and reached agreement with the Food and Drug Administration on the design of its pivotal trials for PN 200. The acid inhibitor includes a non-steroidal anti-inflammatory drug (Nsaid) in a single tablet.

The product is intended to manage pain and inflammation with fewer gastrointestinal side effects compared to an Nsaid taken alone.

Pozen said PN 200 is a product candidate for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing Nsaid-associated gastric ulcers.

The company will begin its phase 3 program within the next few months, officials said.

Pozen is a pharmaceutical company located in Chapel Hill, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.